Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Irish Pharmaceutical Healthcare Association .
Filed returns
45
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement - issues concerning timely reimbursement of medicines in Ireland. (Legislation) | 10 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | US Tariffs and EU - Irish Response (Matters involving public funds) | 8 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) EU General Pharmaceutical Legislation and Irish Government position on Intellectual Property Rights. (ii) EU and Irish competitiveness and the pharmaceutical industry. (Legislation) | 6 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement (Legislation) | 6 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | US Tariffs and EU - Irish Response (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2025 | Irish Pharmaceutical Healthcare Association | Health | Future Framework Agreement - issues concerning timely reimbursement of medicines in Ireland. (Public policy or programme) | 10 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on access to medicines in EU smaller countries/markets and intellectual property rights. (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish… (Legislation) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation and Irish Government position on intellectual Property rights; (ii) Industry position on a National Life Sciences Strategy; (iii) EU and Irish… (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Intellectual Property Rights (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | EU Competitiveness, EU General Pharmaceutical Legislation (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Interdepartmental Policy Co-Ordination. (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2025 | Irish Pharmaceutical Healthcare Association | Health | (i) New Supply Agreement; (ii) Access to new medicines. (Matters involving public funds) | 3 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | EU Commission proposed revision of the EU General Pharmaceutical Legislation and related matters, with particular attention to intellectual property rights provisions, competitiveness and regulatory affairs. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Budget 2025 (Matters involving public funds) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks - (i) Faster Access to new Medicines and (ii) Increased number of Clinical Trials. (Public policy or programme) | 6 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | Issues concerning the timely reimbursement of medicines in Ireland. (Public policy or programme) | 13 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | European Commission Urban Waste Water Treatment Directive (UWWTD), with particular attention to the polluter payers principal and proportional responsibility. (Legislation) | 8 | On lobbying.ie |
| Sep–Dec 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA Programme for Government asks - (i) Support IP Rights for medicines in Europe; (ii) Faster access to new medicines and (iii) A Life Science Policy for Ireland (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | European competitiveness and pharmaceutical industry's role therein. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | IPHA General Election Manifesto asks (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2024 | Irish Pharmaceutical Healthcare Association | Health | (i) Proposed revision of EU General Pharmaceutical Legislation, particularly items relating to incentives/intellectual property rights; (ii) EU wide access to new medicines. (Legislation) | 10 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) European Commission's proposed revision of EU Pharma Legislation and related matters, with particular attention to intellectual property rights provisions and competitiveness. (2) General discussion on issues… (Legislation) | 2 | On lobbying.ie |
| Jan–Apr 2024 | Irish Pharmaceutical Healthcare Association | Health | (1) Budget 2024 - the need for funding of new medicines. (2) Likely no provision for new developments funding to HSE for new medicines in Budget 2024. (3) Absence of funding for new medicines in Budget 2024. (4)… (Matters involving public funds) | 34 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 9 | On lobbying.ie |
| Jan–Apr 2023 | Irish Pharmaceutical Healthcare Association | Health | Revision of pharmaceutical legislation by European Commission. (Legislation) | 10 | On lobbying.ie |
| Sep–Dec 2022 | Irish Pharmaceutical Healthcare Association | Health | Congratulations on appointment. Seek support for fast access to new medicines and for innovation in the EU Pharmaceutical Strategy. (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | EU Pharmaceutical Strategy (Public policy or programme) | 13 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Report on investment in Europe and policy on Advanced Therapy Medicinal Products. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2022 | Irish Pharmaceutical Healthcare Association | Health | Potential meeting with management of investor company in Ireland. (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | (i) WTO TRIPS Waiver of IP rights; (ii) Potential new supply agreement. (iii) Access to potential life sciences strategy. (Matters involving public funds) | 2 | On lobbying.ie |
| May–Aug 2021 | Irish Pharmaceutical Healthcare Association | Health | WTO TRIPS Waiver of IP rights (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | Urging the Government to oppose a waiver of IP rights at the WTO (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2021 | Irish Pharmaceutical Healthcare Association | Health | Extension of framework agreement on medicines. (Public policy or programme) | 14 | On lobbying.ie |
| May–Aug 2020 | Irish Pharmaceutical Healthcare Association | Health | Government policy on access to new medicines (Public policy or programme) | 3 | On lobbying.ie |
| Jan–Apr 2020 | Irish Pharmaceutical Healthcare Association | Health | Importance of a definitive and focused medicines policy, especially regarding access, in the Programme for Government (Public policy or programme) | 12 | On lobbying.ie |
| May–Aug 2019 | Irish Pharmaceutical Healthcare Association | Health | Government policy on access to new medicines (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Irish Pharmaceutical Healthcare Association | Health | Policy Forum for Ireland’s BioPharma Future and ‘BioPharma Ambition 2020 (Public policy or programme) | 1 | On lobbying.ie |
| Jan–Apr 2019 | Irish Pharmaceutical Healthcare Association | Health | To highlight importance of continuity of supply of medicines in Europe post Brexit (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2018 | Irish Pharmaceutical Healthcare Association | Health | IPHA 'Manifesto for Better Health' (Public policy or programme) | 25 | On lobbying.ie |
| Sep–Dec 2018 | Irish Pharmaceutical Healthcare Association | Health | Inclusion of medicine regulation in Brexit withdrawal agreement (Public policy or programme) | 3 | On lobbying.ie |
| May–Aug 2018 | Irish Pharmaceutical Healthcare Association | Health | To arrange briefing meetings with Government Special Advisors (Public policy or programme) | 6 | On lobbying.ie |
| Jan–Apr 2018 | Irish Pharmaceutical Healthcare Association | Health | Government support and involvement in BioPharma Ambition Conference, February 2018 (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2016 | Irish Pharmaceutical Healthcare Association | Health | Negotiation of new Medicines Supply Agreement between IPHA and the State (Public policy or programme) | 14 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 45 | 100.0% |